News

The contract renewal will extend over a five-year horizon. The company began working with the FDA in 2009. Under the terms of the contract, Symphony Health Solutions will

The privately-held Companies being acquired specialize in the development, manufacture and commercialization of complex generic and branded pharmaceutical products. The transaction will provide Impax with a highly-profitable and

In today’s competitive launch environment, biopharmaceutical leaders are utilizing these insights to help them to better understand potential pitfalls and ensure success at market entry. According to research

Drisapersen secured FDA fast track status, making the drug eligible for a rolling review of an NDA and was also granted breakthrough therapy designation in June 2013. Prosensa

This data was presented at the European Association of Dermatology and Venereology (EADV) Congress, in Amsterdam, Netherlands. Secukinumab’s new mode of action stops interleukin-17A (IL-17A), which plays a

These results will be presented at the American Anesthesiology 2014 Annual Meeting in New Orleans, Louisiana. The investigator study was completed at the University of Medicine and Dentistry

Both epilepsy and migraines appear to be triggered by the same coritcal spreading depression (CSD) in the brain, and the difference between the two is the rate of

NPPA is a government regulatory agency that controls the prices of pharmaceutical drugs in India. The company has also received a show cause notice to explain in two

Approved under the tradename Sovaldi in December 2013, Harvoni is a combination of the NS5A inhibitor ledipasvir and the nucleotide analog polymerase inhibitor sofosbuvir. The FDA approval is